Prognostic implications of ezrin expression in human hepatocellular carcinoma.
Ezrin is known to regulate cellular survival, adhesion, migration, and invasion and has been identified as one of the key components of tumor progression and metastasis. The authors investigated ezrin expression in human hepatocellular carcinoma (HCC) and sought to determine its relation with clinicopathologic parameters, patients' outcome, and interacting molecular markers. Ezrin expression was assessed by immunohistochemical staining in 100 surgically resected HCCs using the tissue microarray method. A total of 28 HCCs showed high ezrin immunoreactivity, mainly in cytoplasm. Ezrin expression exhibited a positive correlation with c-Met expression (P = 0.001), but showed no correlation with the expression of CD44s or E-cadherin. HCCs expressing high level of ezrin were significantly associated with advanced TNM stage, poor Edmondson's histological grade, macroscopic portal vein invasion, tumor recurrence, and extrahepatic recurrence (P < 0.05). Univariate analysis showed that HCCs with high ezrin immunoreactivity were strongly associated with unfavorable overall and disease-free survivals than HCCs with low or negative for ezrin immunoreactivity (P = 0.0001 and 0.0011, respectively). Furthermore, multivariate analysis demonstrated that a high level of ezrin expression was independently associated with poor overall survival (hazard ratio, 1.905; P = 0.011). The results suggest that ezrin expression could be a potential predictive marker of progression, metastasis, and prognosis in HCC.
Kang
Yun Kyung
YK
Department of Pathology, Seoul Paik Hospital, Inje University, Korea.
Hong
Seong Woo
SW
Lee
Hyucksang
H
Kim
Woo Ho
WH
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D015820:Cadherins; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000473:pathology* / Q000556:secondary; D003598:Cytoskeletal Proteins; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000473:pathology; D011379:Prognosis; D055815:Young Adult; D000099149:Ezrin
D015415:Biomarkers; D015820:Cadherins; D003598:Cytoskeletal Proteins; D000099149:Ezrin